Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | AVPR1A known ✓ | P37288 | 1/20 | 0.38 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.38 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15663201 | 1.00 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL8065614 | 0.99 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2174 | 0.99 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2432 | 0.99 | MYC (0.45) | MYCWDR5MMEFFAR1AKR1B1 | |
| Oxalic Acid SCHEMBL1616541 | 0.96 | MME (0.44) | MYCWDR5MMEFFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL3473569 | 0.89 | FFAR1 (0.47) | MYCWDR5MMEFFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL2728 | 0.89 | FFAR1 (0.47) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL3121 | 0.89 | MYC (0.43) | MYCWDR5MMEFFAR1AKR1B1 | |
| SCHEMBL2465 | 0.89 | MYC (0.43) | MYCWDR5MMEFFAR1AKR1B1 | |
| Hydrochloric Acid SCHEMBL25430455 | 0.88 | MME (0.47) | MYCWDR5MMEFFAR1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112851549-A | Experiment method for sodium bromide application | 安徽云帆药业有限公司 | 2021-05-28 | — | — | CN | claimed |
| CN-112778159-A | Synthesis method of valsartan intermediate | 安徽云帆药业有限公司 | 2021-05-11 | — | — | CN | claimed |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | HETERO LABS LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| CN-110078640-B | Synthesis method of valsartan intermediate | 浙江美诺华药物化学有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-215327834-U | Secondary amine methyl ester hydrochloride production system | 江苏新瑞药业有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-112851549-A | Experiment method for sodium bromide application | 安徽云帆药业有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-112778159-A | Synthesis method of valsartan intermediate | 安徽云帆药业有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112778159-A | Synthesis method of valsartan intermediate | 安徽云帆药业有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-111393327-A | Preparation method of valsartan intermediate | 河南豫辰药业股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-110028426-A | A kind of diovan foreign matter and preparation method thereof | 浙江华海致诚药业有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-7659406-B2 | Process for preparing valsartan | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-02-09 | — | — | US | disclosed |
| US-20060149079-A1 | Process for preparing valsartan | DR. REDDY'S LABORATORIES, INC. | 2006-07-06 | — | — | US | disclosed |
| WO-2005049587-A1 | PROCESS FOR PREPARATION OF BIPHENYL TETRAZOLE | RANBAXY LABORATORIES LIMITED (IN) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | AGTR2, AGTR1, ADRB1 | ESR2 719/4885GAA 1100/4885AVPR1A 45/4885 |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | AGTR2, AGTR1, ADRB1 | ESR2 719/4885GAA 1100/4885AVPR1A 45/4885 |
| US-20060149079-A1 | Process for preparing valsartan | PREP, TMPRSS15, REN | ESR2 4528/4885GAA 621/4885AVPR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.